Dana–Farber Cancer Institute

Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force (2022) Cuvelier GD, Schoettler M, Buxbaum NP, Pinal-Fernandez I, Schmalzing M, Distler J, Penack O, et al. Journal article, Review article Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea (2021) Ruddy KJ, Schaid DJ, Batzler A, Cecchini RS, Partridge AH, Norman A, Fehrenbacher L, et al. Journal article High Th2 cytokine levels and upper airway inflammation in human inherited T-bet deficiency (2021) Yang R, Weisshaar M, Mele F, Benhsaien I, Dorgham K, Han J, Croft CA, et al. Journal article Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group (2021) Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, et al. Journal article, Review article Idecabtagene vicleucel in relapsed and refractory multiple myeloma (2021) Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, et al. Journal article Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane (2021) O'Shaughnessy J, Schwartzberg L, Piccart M, Rugo HS, Yardley DA, Cortes J, Untch M, et al. Conference contribution Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition (2021) Rogiers A, Da Silva IP, Tentori C, Tondini CA, Grimes JM, Trager MH, Nahm S, et al. Journal article Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set (2020) Chari A, Samur MK, Martinez-Lopez J, Cook G, Biran N, Yong K, Hungria V, et al. Journal article Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study (2020) Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, Shpilberg O, et al. Journal article Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI). (2020) Rogiers A, Tondini C, Grimes JM, Trager MH, Nahm S, Zubiri L, Papneja N, et al. Conference contribution